How much revenue did Agenus generate this year?
Agenus has achieved a revenue of 224.75 M USD this year.
Agenus Revenue 2024
Agenus Revenue
224.75 M USD
Ticker
AGEN
ISIN
US00847G7051
WKN
A1JLKZ
In 2024, Agenus's sales reached 224.75 M USD, a 43.78% difference from the 156.31 M USD sales recorded in the previous year.
The Agenus Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 590.99 | 25,92 |
| 2028e | 445.98 | 34,35 |
| 2027e | 333.63 | 45,92 |
| 2026e | 252.86 | 60,59 |
| 2025e | 195.7 | 78,28 |
| 2024e | 224.75 | 68,17 |
| 2023 | 156.31 | 98,01 |
| 2022 | 98.02 | 89,22 |
| 2021 | 295.67 | 98,83 |
| 2020 | 88.17 | 97,34 |
| 2019 | 150.05 | 102,10 |
| 2018 | 36.78 | 416,49 |
| 2017 | 42.88 | 357,31 |
| 2016 | 22.57 | 678,70 |
| 2015 | 24.82 | 100,00 |
| 2014 | 6.98 | 100,00 |
| 2013 | 3.05 | 82,40 |
| 2012 | 15.96 | 95,79 |
| 2011 | 2.76 | 100,00 |
| 2010 | 3.36 | 96,34 |
| 2009 | 3.33 | 100,00 |
| 2008 | 2.65 | 100,00 |
| 2007 | 5.55 | 2759,42 |
| 2006 | 0.69 | 100,00 |
| 2005 | 0.63 | 100,00 |
| 2004 | 0.71 | 99,29 |
Agenus Revenue, EBIT, Net Income US00847G7051 · A1JLKZ
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Agenus, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Agenus from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Agenus’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Agenus. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Agenus’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Agenus’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Agenus’s growth potential.
Agenus Revenue, EBIT and net profit per share
| Date | Agenus Revenue | Agenus EBIT | Agenus Net Income |
|---|---|---|---|
| 2029e | 590.99 M undefined | 0 undefined | -63.19 M undefined |
| 2028e | 445.98 M undefined | -11.76 M undefined | -72.26 M undefined |
| 2027e | 333.63 M undefined | -53.94 M undefined | -102.52 M undefined |
| 2026e | 252.86 M undefined | -106.26 M undefined | -152.3 M undefined |
| 2025e | 195.7 M undefined | -119.98 M undefined | -189.46 M undefined |
| 2024e | 224.75 M undefined | -69.83 M undefined | -190.75 M undefined |
| 2023 | 156.31 M undefined | -160.11 M undefined | -245.97 M undefined |
| 2022 | 98.02 M undefined | -180.24 M undefined | -220.29 M undefined |
| 2021 | 295.67 M undefined | 37.23 M undefined | -24.14 M undefined |
| 2020 | 88.17 M undefined | -116.01 M undefined | -181.12 M undefined |
| 2019 | 150.05 M undefined | -70.14 M undefined | -107.87 M undefined |
| 2018 | 36.78 M undefined | -123.82 M undefined | -159.9 M undefined |
| 2017 | 42.88 M undefined | -103.8 M undefined | -120.9 M undefined |
| 2016 | 22.57 M undefined | -107.48 M undefined | -127.2 M undefined |
| 2015 | 24.82 M undefined | -80.7 M undefined | -88.08 M undefined |
| 2014 | 6.98 M undefined | -43.32 M undefined | -42.69 M undefined |
| 2013 | 3.05 M undefined | -24.98 M undefined | -33.23 M undefined |
| 2012 | 15.96 M undefined | -6.74 M undefined | -12.12 M undefined |
| 2011 | 2.76 M undefined | -19.09 M undefined | -24.07 M undefined |
| 2010 | 3.36 M undefined | -21.75 M undefined | -22.7 M undefined |
| 2009 | 3.33 M undefined | -27.68 M undefined | -31.11 M undefined |
| 2008 | 2.65 M undefined | -37.84 M undefined | -31.59 M undefined |
| 2007 | 5.55 M undefined | -33.28 M undefined | -38.73 M undefined |
| 2006 | 692,000 undefined | -49.24 M undefined | -52.67 M undefined |
| 2005 | 630,000 undefined | -72.32 M undefined | -74.89 M undefined |
| 2004 | 707,000 undefined | -66.8 M undefined | -56.95 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 707,000 USD | -66.8 M USD | -56.95 M USD |
| 2005 | 630,000 USD | -72.32 M USD | -74.89 M USD |
| 2006 | 692,000 USD | -49.24 M USD | -52.67 M USD |
| 2007 | 5.55 M USD | -33.28 M USD | -38.73 M USD |
| 2008 | 2.65 M USD | -37.84 M USD | -31.59 M USD |
| 2009 | 3.33 M USD | -27.68 M USD | -31.11 M USD |
| 2010 | 3.36 M USD | -21.75 M USD | -22.7 M USD |
| 2011 | 2.76 M USD | -19.09 M USD | -24.07 M USD |
| 2012 | 15.96 M USD | -6.74 M USD | -12.12 M USD |
| 2013 | 3.05 M USD | -24.98 M USD | -33.23 M USD |
| 2014 | 6.98 M USD | -43.32 M USD | -42.69 M USD |
| 2015 | 24.82 M USD | -80.7 M USD | -88.08 M USD |
| 2016 | 22.57 M USD | -107.48 M USD | -127.2 M USD |
| 2017 | 42.88 M USD | -103.8 M USD | -120.9 M USD |
| 2018 | 36.78 M USD | -123.82 M USD | -159.9 M USD |
| 2019 | 150.05 M USD | -70.14 M USD | -107.87 M USD |
| 2020 | 88.17 M USD | -116.01 M USD | -181.12 M USD |
| 2021 | 295.67 M USD | 37.23 M USD | -24.14 M USD |
| 2022 | 98.02 M USD | -180.24 M USD | -220.29 M USD |
| 2023 | 156.31 M USD | -160.11 M USD | -245.97 M USD |
| 2024e | 224.75 M USD | -69.83 M USD | -190.75 M USD |
| 2025e | 195.7 M USD | -119.98 M USD | -189.46 M USD |
| 2026e | 252.86 M USD | -106.26 M USD | -152.3 M USD |
| 2027e | 333.63 M USD | -53.94 M USD | -102.52 M USD |
| 2028e | 445.98 M USD | -11.76 M USD | -72.26 M USD |
| 2029e | 590.99 M USD | 0 USD | -63.19 M USD |
Agenus stock margins US00847G7051 · A1JLKZ
The Agenus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Agenus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Agenus.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Agenus's sales revenue. A higher gross margin percentage indicates that the Agenus retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Agenus's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Agenus's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Agenus's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Agenus. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Agenus's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Agenus Margin History
| Agenus Gross margin | Agenus Profit margin | Agenus EBIT margin | Agenus Profit margin |
|---|---|---|---|
| 2029e | 98.01 % | 0 % | -10.69 % |
| 2028e | 98.01 % | -2.64 % | -16.2 % |
| 2027e | 98.01 % | -16.17 % | -30.73 % |
| 2026e | 98.01 % | -42.02 % | -60.23 % |
| 2025e | 98.01 % | -61.31 % | -96.81 % |
| 2024e | 98.01 % | -31.07 % | -84.87 % |
| 2023 | 98.01 % | -102.43 % | -157.36 % |
| 2022 | 89.22 % | -183.88 % | -224.73 % |
| 2021 | 98.83 % | 12.59 % | -8.16 % |
| 2020 | 97.34 % | -131.58 % | -205.42 % |
| 2019 | 98.01 % | -46.74 % | -71.89 % |
| 2018 | 98.01 % | -336.62 % | -434.7 % |
| 2017 | 98.01 % | -242.09 % | -281.96 % |
| 2016 | 98.01 % | -476.13 % | -563.5 % |
| 2015 | 100 % | -325.18 % | -354.93 % |
| 2014 | 100 % | -620.91 % | -611.87 % |
| 2013 | 82.4 % | -820.36 % | -1,091.36 % |
| 2012 | 95.79 % | -42.23 % | -75.92 % |
| 2011 | 100 % | -692.56 % | -873.26 % |
| 2010 | 96.34 % | -647.41 % | -675.51 % |
| 2009 | 100 % | -830.2 % | -933.05 % |
| 2008 | 100 % | -1,427.54 % | -1,191.66 % |
| 2007 | 98.01 % | -599.39 % | -697.5 % |
| 2006 | 100 % | -7,115.61 % | -7,611.71 % |
| 2005 | 100 % | -11,479.21 % | -11,887.94 % |
| 2004 | 99.29 % | -9,448.37 % | -8,055.45 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 99.29 % | -9,448.37 % | -8,055.45 % |
| 2005 | 100 % | -11,479.21 % | -11,887.94 % |
| 2006 | 100 % | -7,115.61 % | -7,611.71 % |
| 2007 | 98.01 % | -599.39 % | -697.5 % |
| 2008 | 100 % | -1,427.54 % | -1,191.66 % |
| 2009 | 100 % | -830.2 % | -933.05 % |
| 2010 | 96.34 % | -647.41 % | -675.51 % |
| 2011 | 100 % | -692.56 % | -873.26 % |
| 2012 | 95.79 % | -42.23 % | -75.92 % |
| 2013 | 82.4 % | -820.36 % | -1,091.36 % |
| 2014 | 100 % | -620.91 % | -611.87 % |
| 2015 | 100 % | -325.18 % | -354.93 % |
| 2016 | 98.01 % | -476.13 % | -563.5 % |
| 2017 | 98.01 % | -242.09 % | -281.96 % |
| 2018 | 98.01 % | -336.62 % | -434.7 % |
| 2019 | 98.01 % | -46.74 % | -71.89 % |
| 2020 | 97.34 % | -131.58 % | -205.42 % |
| 2021 | 98.83 % | 12.59 % | -8.16 % |
| 2022 | 89.22 % | -183.88 % | -224.73 % |
| 2023 | 98.01 % | -102.43 % | -157.36 % |
| 2024e | 98.01 % | -31.07 % | -84.87 % |
| 2025e | 98.01 % | -61.31 % | -96.81 % |
| 2026e | 98.01 % | -42.02 % | -60.23 % |
| 2027e | 98.01 % | -16.17 % | -30.73 % |
| 2028e | 98.01 % | -2.64 % | -16.2 % |
| 2029e | 98.01 % | 0 % | -10.69 % |
Agenus Aktienanalyse
What does Agenus do?
Agenus Inc is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus started as a small start-up company focusing on the research of antibodies against chronic viral diseases. In 2000, the company developed the first approved therapeutic vaccine against cervical cancer in collaboration with GlaxoSmithKline. Since then, Agenus has expanded its business to the discovery, development, and commercialization of novel antibody and immunotherapies. The company has brought many groundbreaking medications to the market, including a cancer immunotherapy called Prophage, which is approved for the treatment of glioblastoma, an aggressive brain tumor. Agenus' business model focuses on the development of immunotherapies that utilize the body's immune system to fight against cancer or other diseases. The company's research and development programs are divided into three areas: antibody development, immunotherapy, and preclinical developments. Agenus has a comprehensive library of antibodies and utilizes them to develop new and innovative antibodies and antibody conjugates that can be used to treat cancer and autoimmune diseases. The company has also developed a range of immunotherapies aimed at supporting the body's immune system in fighting against cancer and other diseases, including therapies targeting checkpoint inhibitors that enhance the body's immune response to cancer cells. In addition, Agenus has a broad portfolio of preclinical programs aimed at developing new drugs and therapies for the treatment of cancer and other diseases. Agenus has introduced a range of products to the market that can be used for the treatment of cancer and other diseases, including Prophage, a personalized cancer vaccine tailored to each patient for the treatment of glioblastoma. Other products include Zalifrelimab, a checkpoint inhibitor that aims to enhance the body's immune response to cancer, INCAGN2385, another checkpoint inhibitor that enhances T-cell activity in the body, and INCAGN1949, an antibody therapy targeting the GITR protein that can help enhance the immune response against cancer cells. In summary, Agenus is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company has a long history in antibody research and development and has expanded its efforts to develop immunotherapies. Agenus has a comprehensive library of antibodies and has introduced a range of products to the market for the treatment of cancer and other diseases. With a broad portfolio of products and preclinical programs, Agenus remains a key player in the field of immunotherapies and is expected to drive further groundbreaking developments in the future. Agenus ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Agenus's Sales Figures
The sales figures of Agenus originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Agenus’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Agenus's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Agenus’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Agenus stock
How much was the turnover of the company Agenus compared to the previous year?
The revenue of Agenus has increased by 43.78% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Agenus?
The revenue of Agenus is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Agenus measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Agenus so important for investors?
The revenue of Agenus is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Agenus pay?
Over the past 12 months, Agenus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agenus is expected to pay a dividend of 0 USD.
What is the dividend yield of Agenus?
The current dividend yield of Agenus is .
When does Agenus pay dividends?
Agenus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Agenus?
Agenus paid dividends every year for the past 0 years.
What is the dividend of Agenus?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Agenus located?
Agenus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Agenus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Agenus from 7/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/17/2024.
When did Agenus pay the last dividend?
The last dividend was paid out on 7/17/2024.
What was the dividend of Agenus in the year 2023?
In the year 2023, Agenus distributed 0 USD as dividends.
In which currency does Agenus pay out the dividend?
The dividends of Agenus are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Agenus
Our stock analysis for Agenus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agenus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
